Skip to main content

Proton Pump Inhibitors & COVID-19 Hospitalization and Severe COVID-19

Basic Details
Status
Ongoing
Last Updated
Friday, October 31, 2025
Original Posting Date
Health Outcome(s)
COVID-19 hospitalization
Severe COVID-19
Purpose
Drug and Outcome Analysis
Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR
No
Analytic Code Link(s) (2)
COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Inverse Probability of Treatment Weighting Analysis COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Updated Inverse Probability of Treatment Weighting Analysis
Result(s) (1)
Utilization of Proton Pump Inhibitors (PPIs), Single-Agent H2 Receptor Antagonists (H2RAs), and Famotidine in Patients with Gastroesophageal Reflux Disease (GERD): A Descriptive Analysis